C-section and the Neonatal Gut Microbiome Acquisition: Consequences for Future Health.

BACKGROUND: The human gut microbiota is assembled during infancy with an increase in diversity and stability. The correct colonization and the establishment of this microbiome are linked to the early and future health status of the individual. It is known that caesarean delivery alters this optimal microbial foundation. C-section (CS) is a common obstetrician surgery; however, it is not without risk for the mother/infant dyad. The World Health Organization recommends not exceeding 10-15% of the total deliveries; nevertheless, this rate has been increasing rapidly worldwide in the last decades. SUMMARY: This review discloses the clinical parameters for correct CS recommendation. Moreover, the major microbial changes in the infant gut microbiome acquisition as a consequence of delivery mode and medical practices surrounding it, as well as, the early and long-lasting effects for both mother and babies are discussed. In addition, some strategies for the gut microbiota restoration are analysed. The aim of this review is to show the need for the development of strategies for minimizing or limiting the impact of caesarean on the microbiome development, favouring future health.

Safety assessment of a lyophilized biomass of Tetraselmis chuii (TetraSOD®) in a 90 day feeding study.

TetraSOD® is a powder of the lyophilized biomass of Tetraselmis chuii strain CCFM03, a marine microalga with a history of use as feed in the aquaculture industry. Recently, algae including T. chuii have been investigated for their potential use in human food. However, published toxicology studies addressing the safety of T. chuii as a food ingredient are not available. To address this issue, the toxicity of TetraSOD® was evaluated using a 90-day oral toxicology study in rats following the Organisation for Economic Co-operation and Development (OECD) test guideline 408. No treatment-related mortality or clinical signs were noted with TetraSOD® at doses of 625, 1667, or 2500 mg/kg/day. Additionally, no adverse effects on haematology, blood biochemistry, organ weights, gross or histopathology were observed. The Non Observed Adverse Effect Level (NOAEL) for TetraSOD® is greater than the highest tested dose of 2500 mg/kg/day.